# A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

> **NCT05548543** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCP2202
- **DRUG:** RLD2202
- **DRUG:** RLD2203

## Key facts

- **NCT ID:** NCT05548543
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-17
- **Primary completion:** 2022-12-22
- **Final completion:** 2022-12-22
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05548543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05548543, "A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05548543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*